Registration for a live webinar on 'Innovations in antibiotic discovery: combating resistant infections' is now open.
See webinar details- 2023
-
26 min
1. Planning and response to COVID-19: lessons from China and South-East Asia- Prof. Annelies Wilder-Smith
- 2022
-
12 min
2. The emergence of the SARS-CoV-2 Omicron variant- Prof. Emma Thomson
-
14 min
3. How is Omicron different?- Prof. Emma Thomson
- 2021
-
14 min
-
15 min
5. Potential of ‘long-COVID’ in triggering chronic co-pathologies- Dr. İmdat Eroğlu
-
8 min
6. SARS-CoV-2 monoclonal antibody testing in vivo- Prof. Michael Diamond
-
17 min
7. mRNA COVID-19 vaccine efficacy in recovered vs COVID-naive individuals- Prof. E. John Wherry
-
12 min
8. SARS-CoV-2 variants: implications for immunity and vaccine development- Prof. Danny Altmann
-
14 min
-
11 min
10. SARS-COV-2 human monoclonal antibody therapy update- Prof. James Crowe
-
12 min
11. Emergence of blood clotting disorders resulting from COVID vaccines inoculations- Prof. Dr. Sabine Eichinger
-
9 min
12. SARS-CoV-2 evolution within and between individuals- Prof. Katia Koelle
-
10 min
13. Identifying SARS-CoV-2 proteases- Prof. Dr. Christa E. Müller
- Prof. Dr. Michael Gütschow
-
20 min
14. Genetic surveillance and the emergence of SARS-CoV-2 variants- Prof. Emma Thomson
-
16 min
15. The COVID-19 outbreak: April 2021 update- Prof. Jonathan Temte
-
15 min
16. ABO blood groups and SARS-CoV-2 susceptibility- Dr. Sean Stowell
-
20 min
17. Impact of COVID-19 on neuropsychiatric disorders and mental health- Prof. Anthony David
-
20 min
18. The immune system response to the SARS-CoV-2 virus: March 2021 update- Prof. Paul Klenerman
-
6 min
-
12 min
-
13 min
-
18 min
-
17 min
23. SARS-CoV-2 vaccine rollout campaigns- Prof. Luis Graca
-
11 min
-
15 min
25. Interspecies transmission of SARS-CoV-2- Dr. Dalan Bailey
-
12 min
26. Complement activation in COVID-19- Prof. Jeffrey Laurence
-
9 min
27. Human movement patterns and local spread of COVID-19- Prof. Ben Cowling
-
10 min
28. SARS-CoV-2 mutations: phenotypes and implications for vaccine development- Prof. David Montefiori
- 2020
-
18 min
29. The immune system response to the SARS-CoV-2 virus: December 2020 update- Prof. Paul Klenerman
-
20 min
30. Triage and end of life care planning in COVID-19- Prof. Robin Taylor
-
14 min
31. Natural killer cells as COVID-19 therapy- Dr. Philippa Kennedy
-
13 min
32. Update on the SNG001 drug, an INFβ therapy for COVID-19- Prof. Stephen Holgate
-
15 min
-
10 min
34. Identification of a new coronavirus-specific RNA export protein complex- Dr. Montse Bárcena-Martin
-
17 min
35. The neurological symptoms of COVID-19- Dr. Michael Zandi
-
12 min
36. Imperial College London’s saRNA Vaccine - COVAC1- Dr. Katrina Pollock
-
15 min
37. Interferon-α2b as a therapy for COVID-19- Prof. Eleanor N. Fish
-
11 min
38. Potential long-term health effects of a SARS-CoV-2 infection- Prof. Danny Altmann
-
12 min
39. The COVID-19 coronavirus outbreak: October 2020 update- Prof. Jonathan Temte
-
9 min
-
16 min
41. Rheumatic diseases and COVID-19- Dr. Zachary Wallace
-
17 min
42. The cardiovascular complications of SARS-CoV-2 infection- Prof. Srihari Naidu
-
20 min
43. Medical wearable devices for tracking symptoms of COVID-19- Prof. John Rogers
-
21 min
44. Risk of re-emergence of COVID-19 after exit from lockdown- Dr. Leonardo Lopez
-
16 min
45. The evolutionary origin of SARS-CoV-2- Dr. Feng Gao
-
15 min
46. Predicting COVID-19 outbreaks by measuring SARS-CoV-2 RNA in sewage sludge- Prof. Jordan Peccia
-
12 min
47. Approaches for elucidating genetic susceptibility to SARS-CoV-2- Dr. Kenneth Baillie
-
22 min
48. The immune system response to the SARS-CoV-2 virus: July 2020 update- Prof. Paul Klenerman
-
22 min
49. The impact of COVID-19 in the elderly and in care homes- Dr. David Strain
-
19 min
50. Human challenge trials for vaccines against COVID-19- Prof. Peter Smith
-
9 min
51. The development of SARS-CoV-2 vaccines- Prof. Peter Hotez
-
15 min
52. Convalescent plasma therapy as a treatment for COVID-19- Dr. Manu Shankar-Hari
-
12 min
53. Remdesivir COVID-19 clinical trial- Prof. Mahesh Parmar
-
17 min
54. Nanotechnologies in the fight against coronaviruses- Prof. Sabine Szunerits
-
15 min
55. The COVID-19 coronavirus outbreak: May 2020 update- Prof. Jonathan Temte
-
10 min
56. INFβ therapy for COVID-19: the new SNG001 drug- Prof. Stephen Holgate
-
12 min
57. Strategies for exiting the lockdown- Prof. David McCoy
-
17 min
58. SARS-CoV-2 human monoclonal antibody therapy- Prof. James Crowe
-
8 min
59. An FDA approved salivary test for SARS-CoV-2 infection- Prof. Andrew Brooks
-
15 min
60. Development of an intranasal vaccine for SARS-CoV-2- Dr. Scot Roberts
-
13 min
61. The immune system response to the SARS-CoV-2 virus: an update- Prof. Paul Klenerman
-
8 min
62. A novel AIOD-CRISPR system for diagnosis of SARS-CoV-2- Prof. Changchun Liu
-
20 min
63. Development of PRO-140 (Leronlimab) as a treatment for COVID-19- Dr. Jacob Lalezari
-
16 min
64. COVID-19 epidemiology and potential treatments: follow up interview- Prof. Ralph Baric
-
12 min
65. SARS-CoV-2 vaccine development: where are we now?- Prof. Gary Kobinger
-
13 min
66. SARS-CoV-2: What we need to know and possible future therapies- Prof. Stanley Perlman
-
8 min
67. SARS-CoV-2 vaccine: current biological targets and considerations- Dr. Adolfo Garcia-Sastre
-
20 min
68. The current understanding of the biology of the SARS-CoV-2 virus- Prof. Peter Palese
-
16 min
-
17 min
70. The immune system response to the SARS-CoV-2 virus- Prof. Paul Klenerman
-
9 min
71. SARS-CoV-2 vaccine development- Prof. Stanley Plotkin
-
12 min
72. The COVID-19 outbreak: an update on the SARS-CoV-2 virus- Prof. Ralph Baric
-
14 min
73. The COVID-19 coronavirus outbreak: a current view- Prof. Jonathan Temte
-
17 min
74. The COVID-19 coronavirus outbreak: March 2020 update- Prof. Jonathan Temte
Topics Covered
- Mode of action of the Oxford/AstraZeneca DNA vaccine
- Two potential adverse events reported in patients enrolled in the vaccine’s phase 3 trial
- Steps undertaken to determine possible causality between the adverse events and the vaccine
- Differences between RNA and DNA vaccine properties and mechanism of action
- Current status of the trial
- Please note that since the recording of this interview it was determined that "The serious adverse events observed during the trial in these study groups were judged to be unrelated to the study vaccines and occurred at frequencies expected for these conditions in the general population. None of the participants included in this report had any suspected unexpected serious adverse reactions." (Ramasamy et al., The Lancet, November 18, 2020, https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32466-1/fulltext).
Biography
Prof. Saad Shakir MB ChB LRCP&S FRCP FFPM MRCGP, has been working in pharmacovigilance & pharmacoepidemiology for more than a decade. He is the Director of the Drug Safety Research Unit (DSRU) in Southampton, an academic unit associated with the University of Portsmouth, where he leads a research team with an active program for monitoring and studying the safety of medicines. He has worked and advised on many drug safety issues including product withdrawals and major safety hazards. He is the author of many publications on pharmacovigilance and pharmacoepidemiology and a member of the editorial board of the journals of Pharmacoepidemiology and Drug Safety.
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Shakir, S. (2020, November 18). Oxford/AstraZeneca COVID-19 vaccine trial: adverse patient event reports [Audio file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved May 9, 2025, from https://doi.org/10.69645/WRSL8173.Export Citation (RIS)
Publication History
- Published on November 18, 2020
Financial Disclosures
- Prof. Saad Shakir has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Audio Interview
Oxford/AstraZeneca COVID-19 vaccine trial: adverse patient event reports
Published on November 18, 2020
15 min
A selection of talks on Respiratory Diseases
Transcript
Please wait while the transcript is being prepared...
Quiz
Disclaimer: This quiz is intended for learning assessment purposes only and does not grant any certification or credit.
If you are interested in getting a certificate for watching the talk, follow the instructions in this talk's Accreditation Information (where available.)
Hide